Walgreens Spent $12 Billion Buying Its Way Into Healthcare. It Bought a Trap.

In 2019 it was five clinics in Houston, tucked next to the pharmacy counters of an existing chain - a cautious, no-money-down experiment to see whether people would let a doctor see them where they already picked up their prescriptions.¹ Five years later that experiment had become a $12.369 billion non-cash impairment charge, the single largest line in the worst quarter Walgreens had ever reported.⁵ Nobody got the strategy wrong. They got the sequencing wrong. And in the building of a healthcare adjacency, the sequencing was the strategy.

The official story is that Walgreens placed a big, bold bet on primary care and the bet failed because healthcare is hard. That is true and useless. The more precise story is that Walgreens never placed one bet. It placed five, each one larger than the last, each one made before the previous one had proven anything - until it owned a business it could neither fix nor leave.

The thesis was right. The financing was the trap.

Start with what was sound. The drugstore had a problem cash registers couldn't solve: front-of-store retail was being eaten alive, and the pharmacy counter was a commodity. But the corner of every American neighborhood that Walgreens already occupied was prime real estate for the thing healthcare actually lacks - convenient, repeated primary-care contact. Put a doctor in the store and you convert foot traffic into patient panels, prescriptions, and value-based-care payments that reward keeping people healthy. That adjacency thesis was defensible. The error was not believing it. The error was paying for it in installments that each had to be honored before the unit ever earned its keep.

Watch the escalation. The first real money - $1 billion in equity and convertible debt, targeting a 30% stake - came in July 2020, deployed over three years.¹ Fifteen months later, before that capital had even fully landed, Walgreens raised the wager to $5.2 billion to push its ownership from 30% to a controlling 63%, with a public promise of at least 600 co-located clinics by 2025 and 1,000 by 2027.² A controlling stake is a one-way door: once Walgreens consolidated VillageMD onto its own books, every future cash need became Walgreens' problem to fund - or watch its own asset collapse.

Then it got heavier. In November 2022, VillageMD - not Walgreens directly - struck a roughly $8.9 billion deal to acquire Summit Health-CityMD, and Walgreens wrote a $3.5 billion check in debt and equity to fund it, remaining the consolidating shareholder.³ Two months after that, in January 2023, it extended $2.25 billion in senior secured credit facilities to the very business it controlled.⁴ Add it up and the committed capital reaches nearly $12 billion before counting the segment's operating losses. Each step was rational in isolation - you don't let your controlled, debt-laden subsidiary fail. That is precisely what makes it a trap. The logic that justifies the next dollar is strongest exactly when the business is weakest.

What the escalation was supposed to outrun

Here is the mechanism the capital was racing against, and lost. A new clinic is a fixed-cost machine - rent, doctors, equipment - that only turns profitable once it fills a panel of patients. Filling those panels was slower than expected. And in value-based primary care, the unit economics depend on Medicare reimbursement, which moved against them. When Walgreens finally wrote the goodwill down, it named the causes plainly: lower long-term financial performance expectations, Medicare reimbursement headwinds, and slower-than-expected patient growth.⁶ None of those is a surprise that arrives overnight. They are the kind of slow-bleeding signals a pilot is built to catch - the kind a $5.2 billion controlling stake is built to override.

The reckoning came in the quarter ended February 29, 2024. The $12.369 billion charge produced a $5.8 billion hit attributable to Walgreens after tax and minority interest, and a net loss of $5.9 billion for three months of work.⁵ The retreat followed immediately: planned VillageMD closures jumped from 60 clinics to 160.⁶ By August, Walgreens disclosed it was weighing a full or partial sale, citing 'substantial ongoing and expected future cash requirements' - while admitting the unit had defaulted on the $2.25 billion in credit Walgreens itself had extended.⁷ The lender and the borrower were the same company, and even that wasn't enough.

Wasn't this just bad luck on reimbursement?

The fair objection is that Medicare moved the goalposts. Reimbursement headwinds were real, they hit the whole value-based-care sector, and no spreadsheet in 2021 could have priced them perfectly. Maybe Walgreens simply caught a bad wave. There is truth in that - but it lets the structure off the hook. The point of a staged investment is that you don't have to forecast the wave; you ride one round at a time and stop when the data sours. Walgreens did the opposite. It converted optionality into obligation early - taking control in 2021, consolidating the losses, funding an $8.9 billion acquisition in 2022 - so that when the headwinds arrived, it had no off-ramp left. The reimbursement pressure was the trigger. The sequencing was the loaded gun. A staged bettor survives a bad wave; a trapped one drowns in it.

By March 2025 the whole company had run out of road. Walgreens agreed to be taken private by Sycamore Partners at $11.45 a share, plus up to $3.00 more tied to whatever VillageMD might eventually fetch - which was itself to be spun off as a standalone entity, the healthcare dream packaged up and shipped out the door.⁸ That earnout is the tidiest summary of the whole saga: a business Walgreens spent nearly $12 billion to own, valued by its own acquirer as a maybe. The adjacency was never the mistake. The mistake was paying for a five-year experiment as if it were a sure thing, one escalating installment at a time, until the only way out was to stop being a public company at all.